newsfilter
← Latest News
Business Wire·

Axcella Reports Third Quarter Financial Results and Provides Business Update

Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) $34.2 Million Registered Direct